Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)3/20/2026 Flagging notifications
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 March 2026 at 15.40 EE...
Publisher
Finland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 March 2026 at 15.40 EE...
Source route
Continue on orionpharma.com
Leave the platform to read the original full article on the publisher site.
Source: Orion Corporation
Scope: Industry
Related coverage
More related coverage
AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
Industry Shows Appetite For Speedier EU Approval Of Multinational Trials
Media – Announcements (ENG) – Press release (on “il Sole 24 Ore”) – Extract of the call notice of the Shareholders meeting 29.04.2026
Press releaseMar 20, 2026Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipelineProposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,…
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epi...